Inhibikase Therapeutics (IKT) Operating Income Growth (3y) (2023 - 2026)
Inhibikase Therapeutics (IKT) Operating Income Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | 69.02% |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | Inhibikase Therapeutics | 409.23 Mn | 238.86 Mn | - | -55.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.83% |
| Dec 31, 2025 | -47.02% |
| Sep 30, 2025 | -41.43% |
| Jun 30, 2025 | -32.66% |
| Mar 31, 2025 | -46.52% |
| Dec 31, 2024 | -36.88% |
| Sep 30, 2024 | -9.23% |
| Jun 30, 2024 | -24.32% |
| Mar 31, 2024 | -22.13% |
| Dec 31, 2023 | -54.21% |
| Sep 30, 2023 | -92.97% |
| Jun 30, 2023 | -146.54% |
| Mar 31, 2023 | -105.92% |